Adipogenic‐Myogenic Signaling in Engineered Human Muscle Grafts used to Treat Volumetric Muscle Loss
Advanced Biology · 2024
DOI: 10.1002/adbi.202400113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Biology, 2024. Verfasst von Dallas E Altamirano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Translational Tissue Engineering Center, School of Medicine, Johns Hopkins University, Baltimore, MD, 21231, USA. Hauptthemen laut MEDLINE: Tissue Engineering, Muscle Development, Adipogenesis, Muscle, Skeletal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Science Foundation, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Tissue‐engineered muscle grafts (TEMGs) are a promising treatment for volumetric muscle loss (VML). In this study, human myogenic progenitors (hMPs) cultured on electrospun fibrin microfiber bundles and evaluated the therapeutic potential of engineered hMP TEMGs in the treatment of murine tibialis anterior (TA) VML injuries is employed. In vitro, the hMP TEMGs express mature muscle markers by 21 days. Upon implantation into VML injuries, the hMP TEMGs enable remarkable regeneration. To further promote wound healing and myogenesis, human adipose‐derived stem/stromal cells (hASCs) as fibroadipogenic progenitor (FAP)‐like cells with the potential to secrete pro‐regenerative cytokines are incorporated. The impact of dose and timing of seeding the hASCs on in vitro myogenesis and VML recovery using hMP‐hASC TEMGs are investigated. The hASCs increase myogenesis of hMPs when co‐cultured at 5% hASCs: 95% hMPs and with delayed seeding. Upon implantation into immunocompromised mice, hMP‐hASC TEMGs increase cell survival, collagen IV deposition, and pro‐regenerative macrophage recruitment, but result in excessive adipose tissue growth after 28 days. These data demonstrate the interactions of hASCs and hMPs enhance myogenesis in vitro but there remains a need to optimize treatments to minimize adipogenesis and promote full therapeutic recovery following VML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Translational Tissue Engineering Center, School of Medicine, Johns Hopkins University, Baltimore, MD, 21231, USA.
- Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
- Department of Biology, School of Computer, Mathematical & Natural Sciences, Morgan State University, Baltimore, MD, 21251, USA.
- Department of Materials Science & Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
- Department of Chemical & Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
- Institute for Nanobiotechnology (INBT), Johns Hopkins University School of Engineering, Baltimore, MD, 21218, USA.
ORCID-Profile: Warren L Grayson
Förderung
- NIAMS NIH HHS
- National Science Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Altamirano, D. E., Mihaly, E., Emmens, J. D., & Grayson, W. L. (2024). Adipogenic‐Myogenic Signaling in Engineered Human Muscle Grafts used to Treat Volumetric Muscle Loss. Advanced Biology. https://doi.org/10.1002/adbi.202400113
Vancouver
Altamirano DE, Mihaly E, Emmens JD, Grayson WL. Adipogenic‐Myogenic Signaling in Engineered Human Muscle Grafts used to Treat Volumetric Muscle Loss. Advanced Biology. 2024. doi:10.1002/adbi.202400113
BibTeX
@article{Altamirano2024,
author = {Altamirano, Dallas E and Mihaly, Eszter and Emmens, Jalissa D and Grayson, Warren L},
title = {Adipogenic‐Myogenic Signaling in Engineered Human Muscle Grafts used to Treat Volumetric Muscle Loss},
journal = {Advanced Biology},
year = {2024},
doi = {10.1002/adbi.202400113}
}
EUVIMED